Controlled clinical trial of cadralazine as a second-step drug in the treatment of hypertension
Autor: | Mariella Catalano, J. Parini, Arnaldo Libretti, M. Romano |
---|---|
Rok vydání: | 1985 |
Předmět: |
Male
medicine.medical_treatment Hemodynamics Blood Pressure Heart Rate Heart rate medicine Humans Pharmacology (medical) cardiovascular diseases Cadralazine Antihypertensive Agents Pharmacology Clinical Trials as Topic Chemotherapy business.industry Chlorthalidone General Medicine Middle Aged Atenolol Pyridazines Blood pressure Anesthesia Hypertension Drug Therapy Combination Female Diuretic business circulatory and respiratory physiology medicine.drug |
Zdroj: | European Journal of Clinical Pharmacology. 28:135-138 |
ISSN: | 1432-1041 0031-6970 |
Popis: | The antihypertensive efficacy of a new long-lasting vasodilator, cadralazine, and the diuretic chlorthalidone have been compared in hypertensive patients receiving concurrent treatment with atenolol. After a 4-week run-in period with atenolol alone 100 mg/day, two groups of 10 patients whose diastolic blood pressure exceeded 100 mm Hg were given for a period of 65 days either cadralazine 15 mg/day or chlorthalidone 25 mg/day, according to a randomized, double-blind, between-patients design. Compared to atenolol alone, both cadralazine and chlorthalidone induced a statistically and clinically significant decrease in blood pressure. The antihypertensive effect did not differ significantly between groups. Good compensation of the atenolol-induced decrease in heart rate was obtained with cadralazine, whereas during atenolol + chlorthalidone treatment at times the standing heart rate was significantly lower than during treatment with atenolol + cadralazine. Side-effects, many of which were already present during atenolol treatment, occurred with a similar frequency in both groups. It is concluded that atenolol + cadralazine and atenolol + chlorthalidone are equally well tolerated, acceptable and effective in the treatment of hypertension, but that further studies are warranted to explore the potential haemodynamic advantages of the cadralazine + atenolol combination. |
Databáze: | OpenAIRE |
Externí odkaz: |